NexImmune Revenue and Competitors
Estimated Revenue & Valuation
- NexImmune's estimated annual revenue is currently $7M per year.
- NexImmune's estimated revenue per employee is $155,000
Employee Data
- NexImmune has 45 Employees.
- NexImmune grew their employee count by -39% last year.
NexImmune's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CSO - Head Preclinical Immunotherapy and Platform Development | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | SVP Translational Sciences and Medicine | Reveal Email/Phone |
4 | VP, Controller | Reveal Email/Phone |
5 | Head Business Development | Reveal Email/Phone |
6 | SVP, Molecular Engineering & Protein Design | Reveal Email/Phone |
7 | SVP Preclinical Immunotheraphy and Head Cell Biology | Reveal Email/Phone |
8 | EVP, R&D | Reveal Email/Phone |
9 | SVP, Corporate Affairs | Reveal Email/Phone |
10 | VP, Corporate Controller | Reveal Email/Phone |
NexImmune Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is NexImmune?
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIMâ„¢ technology. This nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body's own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial Antigen Presenting Cells (aAPC) that present antigens to T cells eliciting a highly targeted therapy driven by the patient's immune system. These aAPC can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient's body.
keywords:N/A
N/A
Total Funding
45
Number of Employees
$7M
Revenue (est)
-39%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NexImmune News
Neximmune Inc (NEXI) stock is down -89.56% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to...
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to...
Other Companies in Gaithersburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.6M | 45 | 5% | N/A |
#2 | $11.6M | 45 | 0% | N/A |
#3 | $5.2M | 45 | 13% | N/A |
#4 | $10.7M | 46 | 7% | N/A |
#5 | $8.9M | 46 | -13% | N/A |